Inclusion Criteria:

- Leukocytes >= 3,000/mcL

- Histologically or cytologically confirmed soft tissue sarcoma including, but not
limited to, any of the following disease sites:

- Malignant fibrous histiocytoma

- Fibrosarcoma - non infantile

- Leiomyosarcoma - not uterine

- Liposarcoma

- Non-rhabdomyosarcoma soft tissue sarcoma

- Rhabdomyosarcoma, not otherwise specified

- Carcinosarcoma of the uterus

- Dermatofibrosarcoma

- Endometrial stromal sarcoma

- Leiomyosarcoma - uterus

- Recurrent or locally advanced or metastatic disease

- No more than two prior lines of chemotherapy for metastatic disease (not
including adjuvant chemotherapy)

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by
conventional techniques or >= 10 mm by spiral CT scan

- Target measurable lesion must not have been in previous radiation portal, unless
progression of this lesion after radiotherapy has been documented

- ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%

- Life expectancy > 12 weeks

- Recovered from all prior therapy

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- Platelet count >= 100,000/mcL

- Hemoglobin > 9 g/dL

- Total bilirubin =< 1.25 times upper limit of normal (ULN)

- AST and ALT =< 3 times ULN

- Creatinine =< 1.5 times ULN OR creatinine clearance >= 50 mL/min

- Urine protein:creatinine ratio =< 1.0 OR 24-hour urine protein < 1,000 mg

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 8 weeks after
completion of study therapy

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to AZD0530

- No QTc prolongation (defined as a QTc interval >= to 460 msecs) or other significant
ECG abnormalities

- No poorly controlled hypertension (i.e., systolic blood pressure (BP) >= 140 mm Hg,
or diastolic BP >= 90 mm Hg)

- No condition that impairs a patient's ability to swallow AZD0530 tablets, including
any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication
or a requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No intercurrent cardiac dysfunction including, but not limited to, any of the
following:

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- No history of ischemic heart disease, including myocardial infarction

- No uncontrolled intercurrent illness including, but not limited to ongoing or active
infection or psychiatric illness/social situations that would limit compliance with
study requirements

- More than 4 weeks since prior radiotherapy

- More than 7 days since prior and no concurrent prohibited CYP3A4-active agents or
substances

- No other concurrent investigational agents or commercial agents or therapies

- No concurrent combination antiretroviral therapy for HIV-positive patients

- ANC > 1,500/mcL

- No known brain metastases